Autopsy report · NCT01632306

A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer

“Study has been terminated due to slow enrollment.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 months before it started.
• Ran for about 2 years 3 months before it stopped.
• 13 participants enrolled.
• Results were posted on the registry 3 years 5 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Eli Lilly and Company

Sponsor type

Industry

Conditions

Pancreatic Cancer

Interventions

LY2090314; FOLFOX; Gemcitabine; Nab-paclitaxel

Participants

13

Sites

2

Countries

United States

Trials that died the same way

• Memantine and Antipsychotics Use
  “Study terminated due to too slow enrollment” (94% match in meaning)
• Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation
  “Study terminated due to slower than anticipated enrollment.” (94% match in meaning)
• Multi-Center, Prospective, Randomized Controlled Trial Evaluating SkinTE® in the Treatment of Wagner 2 DFUs
  “Study terminated due to slow enrollment and change in strategy.” (93% match in meaning)
• Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia
  “Slow enrollment; study terminated.” (92% match in meaning)
• A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
  “This study terminated prematurely because of slow enrollment” (92% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.